MBX Biosciences, Inc. (MBX) shareholders
Close on Nov 16, 2026Market cap $2.56BP/E –Yield –
Ownership
Institutional holdings as of Jun 30, 2026, from 13F filings
Shares held by institutions
Holders of more than 5%
Latest Schedule 13D (active) or 13G (passive) filed by each holder
| Holder | Shares | % of class | Filing | As of |
|---|---|---|---|---|
| Abigail P. Johnson Joint filing with FMR LLC (15.00%) | 7,224,009 | 15.00% | 13G (passive) amendment | Sep 30, 2026 |
| Patrick J. Heron Joint filing with Frazier Life Sciences X, L.P. (10.80%), Fhmls X, L.P. (10.80%) and 2 more | 5,243,421 | 11.70% | 13D (active) amendment | Aug 6, 2026 |
| Wellington Investment Advisors Holdings LLP Joint filing with Wellington Management Group LLP (10.50%), Wellington Group Holdings LLP (10.50%) and 1 more | 4,977,523 | 10.50% | 13G (passive) amendment | Jun 30, 2026 |
| Edward T. Mathers Joint filing with New Enterprise Associates 17, L.P. (8.10%), NEA Partners 17, L.P. (8.10%) and 9 more | 3,619,474 | 8.10% | 13D (active) amendment | Nov 6, 2025 |
| Orbimed Advisors LLC Joint filing with Orbimed Capital Gp Vii LLC (5.20%) | 3,074,853 | 6.40% | 13D (active) amendment | Aug 6, 2026 |
| FMR LLC Joint filing with Abigail P. Johnson (6.20%) | 2,936,684 | 6.20% | 13G (passive) | Mar 31, 2026 |
| Wellington Management Company LLP Joint filing with Wellington Management Group LLP (7.90%), Wellington Group Holdings LLP (7.90%) and 1 more | 2,638,521 | 7.80% | 13G (passive) amendment | Mar 31, 2025 |
| BlackRock, Inc. | 2,628,181 | 5.50% | 13G (passive) | Jun 30, 2026 |
| Paradigm BioCapital Advisors GP LLC Joint filing with Paradigm BioCapital Advisors LP (5.20%), Senai Asefaw, M.D. (5.20%) | 2,493,015 | 5.20% | 13G (passive) | Jun 16, 2026 |
| Wellington Management Group LLP Joint filing with Wellington Group Holdings LLP (6.80%), Wellington Investment Advisors Holdings LLP (6.80%) and 1 more | 2,266,628 | 6.80% | 13G (passive) amendment | Jun 30, 2025 |
Top institutional holders
13F holdings as of Jun 30, 2026
| Holder | Shares | % of MBX | Value | Change | % of portfolio |
|---|---|---|---|---|---|
| Frazier Life Sciences Management, L.P. | 6,652,013 | 13.81% | $367.19M | – | 8.00% |
| FMR LLC | 5,322,885 | 11.05% | $293.82M | +2,386,201 | 0.01% |
| Wellington Management Group Llp | 4,977,523 | 10.34% | $274.76M | +1,785,699 | 0.05% |
| NEA Management Company, LLC | 3,614,486 | 7.51% | $199.52M | – | 12.56% |
| Orbimed Advisors LLC | 3,428,736 | 7.12% | $189.27M | −209,151 | 3.51% |
| BlackRock, Inc. | 3,323,672 | 6.90% | $183.47M | +382,266 | 0.00% |
| Paradigm Biocapital Advisors LP | 2,508,015 | 5.21% | $138.44M | New | 2.59% |
| NVP Associates, LLC | 2,136,335 | 4.44% | $117.93M | – | 35.93% |
| Deep Track Capital, LP | 1,732,569 | 3.60% | $95.64M | −1,025,000 | 1.39% |
| Polar Capital Holdings Plc | 1,608,514 | 3.34% | $88.79M | −13,672 | 0.21% |
| Vanguard Capital Management LLC | 1,477,388 | 3.07% | $81.55M | −204 | 0.00% |
| Aaron Wealth Advisors LLC | 1,167,799 | 2.42% | $64.46M | −377 | 3.27% |
| Driehaus Capital Management LLC | 1,056,579 | 2.19% | $58.32M | +38,367 | 0.34% |
| Kynam Capital Management, LP | 934,799 | 1.94% | $51.60M | – | 2.85% |
| Woodline Partners LP | 900,092 | 1.87% | $49.69M | +29 | 0.15% |
| Eventide Asset Management, LLC | 873,492 | 1.81% | $48.22M | −16,508 | 0.64% |
| State Street Corp | 864,466 | 1.79% | $47.72M | +77,258 | 0.00% |
| Price T Rowe Associates Inc /Md/ | 814,807 | 1.69% | $44.98M | −214,200 | 0.00% |
| Parkman Healthcare Partners LLC | 800,173 | 1.66% | $44.17M | +136 | 4.52% |
| Geode Capital Management, LLC | 773,072 | 1.61% | $42.68M | +102,687 | 0.00% |
Institutional buying and selling by quarter
Positions opened, added to, reduced and closed by 13F filers
| Quarter | Holders | Shares held | % of shares | New / added | Reduced / closed | Shares bought | Shares sold |
|---|---|---|---|---|---|---|---|
| Q2 2026 | 173 | 55M | 100.0% | 39 / 64 | 49 / 20 | 10M | 7M |
| Q1 2026 | 157 | 53M | 100.0% | 39 / 43 | 47 / 18 | 12M | 6M |
| Q4 2025 | 138 | 48M | 100.0% | 45 / 53 | 25 / 25 | 7M | 7M |
| Q3 2025 | 118 | 48M | 99.2% | 39 / 30 | 29 / 9 | 15M | 4M |
| Q2 2025 | 88 | 37M | 76.6% | 21 / 40 | 14 / 12 | 5M | 4M |
| Q1 2025 | 79 | 36M | 74.1% | 27 / 24 | 15 / 10 | 4M | 1M |
| Q4 2024 | 63 | 33M | 68.4% | 33 / 11 | 8 / 15 | 3M | 1M |
| Q3 2024 | 45 | 30M | 62.9% | 45 / 0 | 0 / 0 | 30M | 0M |
Top mutual fund and ETF holders
Latest monthly portfolio reports (Form N-PORT)
185 funds held MBX in Q2 2026, 35% of their shares through ETFs. Each fund counts once per quarter, from its quarter-end report.
| Fund | Shares | % of MBX | Value | % of fund | As of |
|---|---|---|---|---|---|
| Vanguard Total Stock Market Index Fund | 1,135,375 | 2.36% | $62.67M | 0.00% | Jun 30, 2026 |
| Eventide Healthcare & Life Sciences Fund | 873,492 | 1.81% | $48.22M | 2.70% | Jun 30, 2026 |
| Fidelity Advisor Biotechnology Fund | 817,600 | 1.70% | $53.90M | 2.45% | Jul 31, 2026 |
| iShares Russell 2000 ETF | 796,629 | 1.65% | $43.97M | 0.05% | Jun 30, 2026 |
| Fidelity Stock Selector Small Cap Fund | 636,100 | 1.32% | $41.94M | 0.57% | Jul 31, 2026 |
| Select Health Care Portfolio | 600,000 | 1.25% | $18.88M | 0.33% | May 31, 2026 |
| T. Rowe Price Health Sciences Fund, Inc. | 586,309 | 1.22% | $32.36M | 0.27% | Jun 30, 2026 |
| Fidelity Small Cap Growth Fund | 416,420 | 0.86% | $27.45M | 0.31% | Jul 31, 2026 |
| Fidelity Series Small Cap Opportunities Fund | 365,200 | 0.76% | $24.08M | 0.51% | Jul 31, 2026 |
| Fidelity Small Cap Index Fund | 339,492 | 0.70% | $22.38M | 0.07% | Jul 31, 2026 |
| BlackRock Health Sciences Opportunities Portfolio | 333,350 | 0.69% | $10.49M | 0.18% | May 29, 2026 |
| Fidelity Advisor Health Care Fund | 328,000 | 0.68% | $21.63M | 0.69% | Jul 31, 2026 |
| Fidelity Fund | 321,100 | 0.67% | $17.72M | 0.20% | Jun 30, 2026 |
| Vanguard Extended Market Index Fund | 305,998 | 0.64% | $16.89M | 0.02% | Jun 30, 2026 |
| VIP Contrafund Portfolio | 286,900 | 0.60% | $15.84M | 0.05% | Jun 30, 2026 |
Officers, directors and major owners
People who filed Forms 3, 4 or 5 in the last two years
| Name | Role | Shares owned | % of shares | Latest filing |
|---|---|---|---|---|
| Steven L. Hoerter | Chairman, President and CEO, Director | 98,045 | 0.20% | Nov 12, 2026 |
| P. Kent Hawryluk | President & CEO, Director | 1,214,444 | 2.52% | May 8, 2026 |
| Salomon Azoulay | Chief Medical Officer | 14,026 | 0.03% | Nov 5, 2026 |
| John W. Smither | Chief Financial Officer | 28,000 | 0.06% | Aug 4, 2026 |
| Richard Bartram | Chief Financial Officer | 15,000 | 0.03% | Feb 3, 2026 |
| Peter Radovich | Director | – | – | Oct 22, 2026 |
| Patrick J. Heron | Director, 10% owner | 3,927,774 | 8.16% | Jun 5, 2026 |
| Ora H. Pescovitz | Director | 24,329 | 0.05% | Jun 5, 2026 |
| Steven Ryder | Director | – | – | Jun 5, 2026 |
| Edward T. Mathers | Director | 3,614,486 | 7.51% | Jun 5, 2026 |
| Tiba Aynechi | Director | 1,386,335 | 2.88% | Jun 5, 2026 |
| Laurie Stelzer | Director | – | – | Jun 5, 2026 |
| James M. Cornelius | Director | 102,082 | 0.21% | Jun 6, 2025 |
| Carl L. Gordon | Director, 10% owner | 747,887 | 1.55% | Feb 19, 2025 |
| Advisors Llc Orbimed | Director, 10% owner | 3,812,215 | 7.92% | Feb 19, 2025 |
| Capital GP VII LLC OrbiMed | Director, 10% owner | – | – | Feb 19, 2025 |
| Genesis GP LLC OrbiMed | Director, 10% owner | 3,255,000 | 6.76% | Feb 19, 2025 |
| Fhmls X, L.L.C. | 10% owner | – | – | Sep 30, 2025 |
| James N. Topper | 10% owner | – | – | Sep 30, 2025 |
| Frazier Life Sciences X, L.P. | 10% owner | – | – | Sep 30, 2025 |
| Fhmls X, L.P. | 10% owner | 9,772,214 | 20.29% | Sep 30, 2025 |
Insider trades
Common stock transactions reported on Form 4, newest first
| Insider | Date | Transaction | Shares | Price | Value | Shares after |
|---|---|---|---|---|---|---|
| Steven L. Hoerter Chairman, President and CEO, Director | Nov 10, 2026 | Sale | −4,893 | $54.82 | $268.23K | 78,045 |
| Salomon Azoulay Chief Medical Officer | Nov 4, 2026 | Sale | −373 | $53.96 | $20.13K | 14,026 |
| Salomon Azoulay Chief Medical Officer | Aug 4, 2026 | Sale | −370 | $65.77 | $24.33K | 14,399 |
| John W. Smither Chief Financial Officer | Aug 3, 2026 | Award | +28,000 | – | – | 28,000 |
| Steven L. Hoerter President and CEO, Director | Aug 3, 2026 | Award | +71,000 | – | – | 82,938 |
| Salomon Azoulay Chief Medical Officer | May 8, 2026 | Option exercise | +55,000 | $10.46 | $575.30K | 69,769 |
| Salomon Azoulay Chief Medical Officer | May 8, 2026 | Sale(10b5-1 plan) | −15,003 | $38.30 | $574.61K | 14,769 |
| Salomon Azoulay Chief Medical Officer | May 8, 2026 | Option exercise | +15,003 | $16.00 | $240.05K | 29,772 |
| Salomon Azoulay Chief Medical Officer | May 8, 2026 | Sale(10b5-1 plan) | −55,000 | $38.38 | $2.11M | 14,769 |
| P. Kent Hawryluk President & CEO, Director | May 6, 2026 | Sale | −607 | $29.54 | $17.93K | 727,667 |
| Salomon Azoulay Chief Medical Officer | May 6, 2026 | Sale | −231 | $29.54 | $6.82K | 14,769 |
| Steven L. Hoerter Director | May 1, 2026 | Award | +11,938 | – | – | 11,938 |
| P. Kent Hawryluk President & CEO, Director | Mar 13, 2026 | Buy | +18,500 | $28.41 | $525.59K | 486,777 |
| P. Kent Hawryluk President & CEO, Director | Feb 26, 2026 | Option exercise | +28,768 | $16.00 | $460.29K | 728,274 |
| Salomon Azoulay Chief Medical Officer | Feb 2, 2026 | Award | +15,000 | – | – | 15,000 |
| P. Kent Hawryluk President & CEO, Director | Feb 2, 2026 | Award | +35,250 | – | – | 699,506 |
| Richard Bartram Chief Financial Officer | Feb 2, 2026 | Award | +15,000 | – | – | 15,000 |
| P. Kent Hawryluk President & CEO, Director | Oct 24, 2025 | Option exercise | +182,859 | $3.25 | $594.29K | 664,256 |
| P. Kent Hawryluk President & CEO, Director | Oct 20, 2025 | Buy | +20,000 | $13.64 | $272.80K | 468,277 |
| Steven L. Hoerter Director | Oct 17, 2025 | Buy | +20,000 | $13.25 | $265.00K | 20,000 |
| Fhmls X, L.P. 10% owner | Sep 26, 2025 | Buy | +666,666 | $18.00 | $12.00M | 5,219,440 |
| Ora H. Pescovitz Director | Apr 8, 2025 | Buy | +7,693 | $5.89 | $45.31K | 24,329 |
| Carl L. Gordon Director, 10% owner | Feb 18, 2025 | Buy | +94,100 | $10.84 | $1.02M | 747,887 |
| Carl L. Gordon Director, 10% owner | Feb 18, 2025 | Buy | +49,070 | $10.84 | $531.92K | 3,255,000 |
| Genesis GP LLC OrbiMed Director, 10% owner | Feb 18, 2025 | Buy | +49,070 | $10.84 | $531.92K | 3,255,000 |
| Genesis GP LLC OrbiMed Director, 10% owner | Feb 18, 2025 | Buy | +94,100 | $10.84 | $1.02M | 747,887 |
| Carl L. Gordon Director, 10% owner | Feb 14, 2025 | Buy | +17,962 | $9.90 | $177.82K | 3,176,390 |
| Carl L. Gordon Director, 10% owner | Feb 14, 2025 | Buy | +29,540 | $9.85 | $290.97K | 3,205,930 |
| Genesis GP LLC OrbiMed Director, 10% owner | Feb 14, 2025 | Buy | +29,540 | $9.85 | $290.97K | 3,205,930 |
| Genesis GP LLC OrbiMed Director, 10% owner | Feb 14, 2025 | Buy | +17,962 | $9.90 | $177.82K | 3,176,390 |
| P. Kent Hawryluk President & CEO, Director | Feb 4, 2025 | Buy | +50,000 | $10.69 | $534.50K | 448,277 |
| Edward T. Mathers Director, 10% owner | Sep 16, 2024 | Buy | +500,000 | $16.00 | $8.00M | 3,614,486 |
| Edward T. Mathers Director, 10% owner | Sep 16, 2024 | Conversion | +2,091,383 | – | – | 3,114,486 |
| Edward T. Mathers Director, 10% owner | Sep 16, 2024 | Conversion | +1,023,103 | – | – | 1,023,103 |
| Tiba Aynechi Director | Sep 16, 2024 | Conversion | +1,386,335 | – | – | 1,386,335 |
| Tiba Aynechi Director | Sep 16, 2024 | Buy | +750,000 | $16.00 | $12.00M | 2,136,335 |
| James M. Cornelius Director | Sep 16, 2024 | Conversion | +102,082 | – | – | 102,082 |
| Fhmls X, L.P. 10% owner | Sep 16, 2024 | Buy | +625,000 | $16.00 | $10.00M | 4,552,774 |
| Fhmls X, L.P. 10% owner | Sep 16, 2024 | Conversion | +3,927,774 | – | – | 3,927,774 |
| Forest Baskett 10% owner | Sep 16, 2024 | Conversion | +2,091,383 | – | – | 3,114,486 |
| Forest Baskett 10% owner | Sep 16, 2024 | Conversion | +1,023,103 | – | – | 1,023,103 |
| Forest Baskett 10% owner | Sep 16, 2024 | Buy | +500,000 | $16.00 | $8.00M | 3,614,486 |
| Scott D. Sandell 10% owner | Sep 16, 2024 | Conversion | +2,091,383 | – | – | 3,114,486 |
| Scott D. Sandell 10% owner | Sep 16, 2024 | Buy | +500,000 | $16.00 | $8.00M | 3,614,486 |
| Scott D. Sandell 10% owner | Sep 16, 2024 | Conversion | +1,023,103 | – | – | 1,023,103 |
| Paul Edward Walker 10% owner | Sep 16, 2024 | Conversion | +2,091,383 | – | – | 3,114,486 |
| Paul Edward Walker 10% owner | Sep 16, 2024 | Buy | +500,000 | $16.00 | $8.00M | 3,614,486 |
| Paul Edward Walker 10% owner | Sep 16, 2024 | Conversion | +1,023,103 | – | – | 1,023,103 |
| P. Kent Hawryluk President & CEO, Director | Sep 16, 2024 | Conversion | +115,914 | – | – | 398,277 |
| P. Kent Hawryluk President & CEO, Director | Sep 16, 2024 | Conversion | +283,846 | – | – | 481,397 |
| Biomedical Innovation Master Investors (Cayman) II L.P. Wellington 10% owner | Sep 16, 2024 | Conversion | +403,787 | – | – | 1,790,122 |
| Biomedical Innovation Master Investors (Cayman) II L.P. Wellington 10% owner | Sep 16, 2024 | Conversion | +1,386,335 | – | – | 1,386,335 |
| Rick Yang 10% owner | Sep 16, 2024 | Conversion | +2,091,383 | – | – | 3,114,486 |
| Rick Yang 10% owner | Sep 16, 2024 | Buy | +500,000 | $16.00 | $8.00M | 3,614,486 |
| Rick Yang 10% owner | Sep 16, 2024 | Conversion | +1,023,103 | – | – | 1,023,103 |
| Advisors Llc Orbimed Director, 10% owner | Sep 16, 2024 | Buy | +250,000 | $16.00 | $4.00M | 653,787 |
| Advisors Llc Orbimed Director, 10% owner | Sep 16, 2024 | Conversion | +403,787 | – | – | 403,787 |
| Advisors Llc Orbimed Director, 10% owner | Sep 16, 2024 | Buy | +500,000 | $16.00 | $8.00M | 3,158,428 |
| Advisors Llc Orbimed Director, 10% owner | Sep 16, 2024 | Conversion | +2,658,428 | – | – | 2,658,428 |
| Anthony A. Florence Jr. 10% owner | Sep 16, 2024 | Conversion | +2,091,383 | – | – | 3,114,486 |
Awards, option exercises, tax withholding and gifts are shown alongside open-market buys and sales. Each name links to the filing on SEC EDGAR.
Short interest
Shares sold short and not yet bought back, as of Oct 30, 2026 (FINRA, reported twice a month)
Shares sold short, last 12 months
Short sale volume counts trades marked short on any given day, including market-maker hedging, so it runs far higher than the share of MBX Biosciences's stock actually held short. Settlement fails (shares not delivered on time) peaked at 3,456 shares on Aug 27, 2026 over the last 90 days.
Planned insider sales
Notices of proposed sale filed on Form 144 before shares are sold
| Seller | Filed | Shares | Market value | Planned sale | Acquired through |
|---|---|---|---|---|---|
| Steven L. Hoerter Director | Nov 10, 2026 | 4,893 | $268.25K | Nov 10, 2026 | Restricted Stock Vesting |
| Salomon Azoulay Officer | Nov 4, 2026 | 373 | $20.13K | Nov 4, 2026 | Restricted Stock Vesting |
| P. Kent Hawryluk Former Officer | Aug 17, 2026 | 3,745 | $255.74K | Aug 17, 2026 | Restricted Stock Vesting |
| Salomon Azoulay Officer | Aug 4, 2026 | 370 | $24.34K | Aug 4, 2026 | Restricted Stock Vesting |
| P. Kent Hawryluk Officer, Director | Aug 4, 2026 | 936 | $61.56K | Aug 4, 2026 | Restricted Stock Vesting |
| Richard Bartram Former Officer | Jun 10, 2026 | 9,167 | $280.01K | Jun 10, 2026 | Stock Option Exercise |
| Richard Bartram Former Officer | Jun 9, 2026 | 10,833 | $321.27K | Jun 9, 2026 | Stock Option Exercise |
| Richard Bartram Former Officer | May 13, 2026 | 15,000 | $554.30K | May 13, 2026 | Option Granted - 08/15/2023 |
| Richard Bartram Former Officer | May 11, 2026 | 22,500 | $991.90K | May 11, 2026 | Option Granted - 04/20/2022 |
| Salomon Azoulay Officer | May 8, 2026 | 70,003 | $2.69M | May 8, 2026 | Option Granted - 09/12/2024 |
| Richard Bartram Former Officer | May 8, 2026 | 10,000 | $379.56K | May 8, 2026 | Option Granted - 04/20/2022 |
| Richard Bartram Former Officer | May 7, 2026 | 10,000 | $322.05K | May 7, 2026 | Option Granted 04/20/2022 |
| Salomon Azoulay Officer | May 6, 2026 | 231 | $6.82K | May 6, 2026 | Restricted Stock Vesting |
| P. Kent Hawryluk Officer, Director | May 6, 2026 | 607 | $17.93K | May 6, 2026 | Restricted Stock Vesting |
| Richard Bartram Former Officer | May 1, 2026 | 5,000 | $159.00K | May 1, 2026 | Options Granted - 04/20/2022 |
See a number that looks wrong?